English

• Quinazolinone ring skeleton widely exists in natural products and drug molecules. Quinazolinones shows good biological activities in anti-tumor, antibacterial, anti-inflammatory and antihypertension. Similarly, 4-oxoquinazoline natural products are also used as privileged motifs in drug research due to their diverse pharmacological activities (Fig. 1) [1-5]. The synthetic methods of quinazoline have been reported by many researchers [6-10]. However, there are few reports on the simple synthesis of polycyclic quinazolines, especially chiral ones [11-13]. Recently, some research groups attempted to develop methods for the synthesis of tricyclic pyroquinazolone compounds using 4-oxoquinazoline-tethered alkenes or functional group-substituted alkyl chain [14-20]. Notably, in 2021, Dong's group [14] reported a deacylation-aided C–H alkylative annulation of arenes or heteroarenes, in which tricyclic pyroquinazolones were provided in moderate yields (Scheme 1a). Procter [15] disclosed an enantioselective copper-catalyzed borylative cyclization for the assembly of privileged pyroquinazolone motifs (Scheme 1b). Very recently, Wu [16], Jin [17,18], He [19] reported a similar photocatalytic synthesis for polycyclic pyroquinazolones (Scheme 1c). Though there are many ways to prepare achiral or racemic products, few enantioselective synthetic methods could be extended to multifunctionalization of pyroquinazolone scaffolds [21-23]. Enantiomers often exhibit different bioactivities [24], and it is undoubtedly important to prepare these compounds with enantiomeric purity. Therefore, the efficient synthesis of these known and unknown bioactive compounds urgently requires a new asymmetric protocol to build cyclic pyroquinazolone blocks.

  Figure 1

  

  Figure 1.  Natural products and drug molecules of 4-oxoquinazoline skeleton.

  DownLoad: Full-Size Img PowerPoint

  Scheme 1

  

  Scheme 1.  Selective cyclization of 4-oxoquinazolines with tethered alkenes or functional group-substituted alkyl chain.

  DownLoad: Full-Size Img PowerPoint

  Secondary phosphine oxides (SPOs) refer to phosphine oxides containing one hydrogen on the phosphorus atom [25-31]. Compared with most complex phosphine ligands, they are more stable in air and moisture and easy to prepare and preserve. In the presence of alkali, Lewis acid or transition metal, phosphorus can be P(Ⅴ)–P(Ⅲ) tautomerized, in which the stereochemical information around the phosphorus can be retained. For being economical, less toxic and having various coordination modes, Ni [32-35] and Al [36,37] are widely used in their respective catalytic reactions. Nakao [38-40] and colleagues reported direct C-H activation of pyridine compounds catalyzed by Ni-Al bimetallic catalysts with monophosphine ligands or NHC. In the following time, there are also related reports from other groups [41-45]. Their research showed that the Ni-Al catalytic system has a good activation effect on the C-H activation at specific potential electron-deficient sites such as heterocyclic compounds and formamide groups, which provides a possible way for the asymmetric catalytic synthesis of chiral heterocyclic and cyclized compounds. In 2013, Cramer [46] and co-workers discovered that a kind of chiral SPO can provide good activity and enantioselectivity in Ni-Al bimetallic catalyzed hydrocarbamoylation of alkenes. Recently, Ye's group [47-50] also conducted corresponding research in this field. Intramolecular C-H alkylation is undoubtedly a simple and straightforward way for the synthesis of chiral fused 4-oxoquinazoline derivatives. However, suitable catalytic systems have hardly been reported so far. Herein, we disclose the development of two new types of diamine-derived chiral SPO ligands with sterically bulky groups and their application in Ni-Al bimetallic catalytic cyclization of 4-oxoquinazolines with tethered alkenes (Scheme 1d).

  Initially, we began to explore the model catalytic reaction of substrates 1ub with traditional SPOs as ligands (Table S1 in Supporting information and Scheme 2, SPO1-5). But the reaction activity or enantioselectivity was poor. Therefore, we realized that modification of the five-membered P-heterocyclic secondary phosphine oxides is necessary and the introduction of large steric substituents into the framework might finely adjust the stereostructure and electrical properties of the ligands and corresponding catalysts. Following this concept, two types of SPOs were designed and successfully synthesized from readily available chiral amines or amino acids (Scheme 2, SPO6-11) [51-54].

  Scheme 2

  

  Scheme 2.  Traditional chiral SPO1-5 and synthesis of new chiral SPO6-11.

  DownLoad: Full-Size Img PowerPoint

  With the developed ligands in hand, we continued to conduct ligand screening for substrate 1a (Table 1). Taddol-derived SPO1-2 were found to give the target product 2a in poor yield and ee value (Table 1, entries 1 and 2). In contrast, with traditional N-P-N SPO3-4 instead, the yield of 2a was greatly improved, but the ee value was still not good (Table 1, entries 3-5). Encouragingly, SPO6 provided product 2a with 72% ee, although the yield was only 33%. An interesting phenomenon was also observed, employing SPO7 as the ligand, 3a was obtained as the main product in 87% yield. This implies regioselection can be tuned by appropriate steric effect of the ligand. Further investigations were performed for the prepared SPOs bearing large steric hindrance groups on the N-branched chain (Table 1, entries 8-11). Luckily enough, product 2a was given in 86% yield with 86% ee when SPO10 was used. Through optimization experiments, the optimal reaction conditions of the template reaction were finally determined. The desired product 2a was afforded in 94% yield with 97% ee (Table 1, entry 19).

  Table 1

  

  Table 1.  Conditions optimization. ^a

  DownLoad: CSV

  Under the above optimized reaction conditions, the reaction was further extended to a series of substrates with functional groups at different sites to test the generality (Scheme 3). Substituent effect of monoalkene-tethered 4-oxoquinazoline was first investigated. When the substituents were electron donor groups (2b-2h, 2o), there is less influence on the yield and ee value of the product. The reactions provided the corresponding products in 71%–95% yields and 86%-99% ee. For the substrates with electron-withdrawing substituents, such as CF₃, F and ester groups (2i-2m), the reaction activity became poor under the standard conditions. After further optimizing the conditions, acceptable yields were obtained, and the ee values also remained at a high level. For some substrates with large π conjugated groups, reaction results were still good enough under the corresponding conditions to provide 2n, 2p and 2q in 77%–93% yields and 90%–96% ee. Notably, when an additional 6-alkenyloxy substituent was introduced into the skeleton, the enantioselectivity remained excellent (2o) despite a decrease in reactivity. It is speculated that the additional alkenyl group might participate in the coordination competition of Ni, resulting in the reduction of catalytic activity.

  Scheme 3

  

  Scheme 3.  Scope of substrates. Standard reaction conditions: 1 (0.2 mmol), dioxane (2.0 mL), 5 mol% Ni(cod)₂, 40 mol% AlMe₃, 10 mol% SPO10, room temperature, under N₂ for 24 h; ^a 10 mol% Ni(COD)₂, 15 mol% PPh₃, 48 h; ^b 10 mol% Ni(cod)₂, 60 h; ^c 10 mol% Ni(cod)₂, 10 mol% SPO6, 15 mol% PPh₃, 80 ℃, 48 h; ^d 10 mol% Ni(cod)₂, 10 mol% SPO11, 40 ℃, 72 h; ^e 10 mol% Ni(cod)₂, 10 mol% SPO11, 60 ℃, 60 h; ^f 10 mol% Ni(cod)₂; ^g 10 mol% Ni(cod)₂, 10 mol% SPO6, 15 mol% PPh₃, 60 ℃, 72 h; ^h 10 mol% Ni(cod)₂, 40 ℃, 80 h; ⁱ 10 mol% Ni(cod)₂, 15 mol% PPh₃, 80 ℃, 48 h; ^j 10 mol% Ni(cod)₂, 80 ℃, 48 h.

  DownLoad: Full-Size Img PowerPoint

  Next, N-heterocyclic substrate 1r was tested. Unfortunately, the ee value of the resulting product 2r was only 51%. Further ligand screening indicated that SPO6 was slightly better than SPO10, and the ee value of the product increased to 53%. Using SPO10 as ligand, the reaction of 4-pyrimidinone substrates 1s and 1t yielded corresponding 2s with 70% ee and racemic 2t. After changing to SPO11, the enantioselectivity of the reactions was improved to 80% and 48%, respectively. Subsequently the suitability of substrates tethered with different N-substituted alkene chains (1ua-1ue) were also investigated. With SPO10 as the ligand, all the catalytic reactions except that of substrate 1uc achieved satisfactory yields and enantioselectivities. These results demonstrate that the alkyl group attached to the end of the olefin chain has less influence on the reaction. However, when phenyl group was directly linked to the end of olefin, product 2uc was only obtained with 25% yield and 47% ee under the standard conditions. In the case of optimized ligand SPO6, 2uc was finally prepared in 87% yield and 70% ee. Changing the linked phenyl group into benzyl or phenylpropyl, interestingly, SPO10 in turn afforded product 2ud or 2ue very well. For substrates 1uf and 1ug with added F atom on the benzene ring of the alkyl chain, no reaction occurred under the standard reaction conditions. After heating to 80 ℃ and adding 15 mol% PPh₃, the reaction went well, providing 2uf and 2ug with satisfactory results. Similarly, the activity also decreased when isobutyl was assembled to the olefin chain. The final ee value of 2uh obtained at 80 ℃ was 80%. The configuration of C3 was successfully identified as S by single-crystal X-ray diffraction of 2q.

  It is also worth noting that the reaction did not proceed as expected when the benzene ring of the substrate contains halogen groups such as Cl and Br. After further exploration (Scheme 4a), it was revealed that the exact reason is that the Cl group became active and was preferentially replaced by methyl group from AlMe₃ under the catalysis of IPr. So the corresponding products are C and D, not B. In order to obtain a product with a larger ring, substrate E with a longer N-substituted olefin chain was also tried, but the experimental result were not consistent with our design (Scheme 4b). An interesting phenomenon was noted that the hydrogen of olefin migrated and a five-membered ring product G was finally generated with almost 100% conversion when achiral ligand IPr was used for the catalysis. Replacing IPr with chiral SPO10, however, the five-membered ring product G and the six-membered ring product F coexisted with moderate ee values. This shows that the structure of the ligand affect the regioselectivity of the reaction significantly.

  Scheme 4

  

  Scheme 4.  Extended experiments.

  DownLoad: Full-Size Img PowerPoint

  To understand the mechanism, the deuterated substrate D-1aa (88% D) of 1a was prepared from deuterated material (Scheme 5a). In the complete reaction of D-1aa, 54% of deuterium was transferred to the terminal carbon of the alkene moiety, and 36% of deuterium was added to the intermediate carbon atom of the ene. A competitive experiment between D-1aa and 1h revealed that there was no deuterium scrambling distribution. In addition, no significant kinetic isotope effect was observed in the competitive experiment (KIE = 1.0). In order to verify whether SPO has valence change, ³¹P NMR of SPO10 was identified (Scheme 5b). It was found that the chemical shift of ³¹P NMR changed from 10.59 ppm to 13.05 ppm after adding AlMe₃. This shows that SPO and AlMe₃ indeed interact to change the valence state of phosphine, and then SPO-AlMe₂ coordinate with nickel [46]. On the basis of our experimental exploration and references [46,50,55], a possibly plausible catalytic cycle is presented (Scheme 5c). First, phosphine oxide is converted into trivalent phosphine under the activation of AlMe₃, which then forms a complex with Ni. Al coordinates with the sp²-N atom of the substrate to help the location, then Ni carries out oxidative addition and reductive elimination through the conventional C-H activation steps to generate products. Chiral SPO acts as a ligand and plays a role in chiral induction.

  Scheme 5

  

  Scheme 5.  Plausible mechanism.

  DownLoad: Full-Size Img PowerPoint

  In summary, we have developed two new types of chiral secondary phosphine oxides (SPOs) with bulky and adaptable structures, and their application in the nickel-catalyzed intramolecular enantioselective C−H cyclization of 4-oxoquinazolines with tethered alkenes. For the first time, a new class of chiral tricyclic pyrroloquinazolinone compounds were successfully prepared in up to 95% yield and 99% ee under the mild conditions via the simple Ni-Al bimetallic catalysis. The introduction of sterically hindered chiral amines prepared from readily available chiral raw materials makes the developed ligands significantly superior to the traditional SPOs in this asymmetric catalytic reaction. The effective regulation of enantio- and regioselectivity of the reaction by ligand structure was also demonstrated. The development of Ni-SPO-Al catalytic system and better substrate applicability research are ongoing.

  Declaration of competing interest

  The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

  Acknowledgments

  We thank the National Natural Science Foundation of China (No. 22071270), Science and Technology Program of Guangzhou (20220602JBGS02), Guangdong Province Zhu Jiang Talents Plan (No. 2016ZT06C090) and Guangzhou City Talents Plan (No. CYLJTD-201609) for financial support.

  Supplementary materials

  Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2022.108017.

  
  
• 1. [1]

     A. Al-Shamma, S. Drake, D.L. Flynn, et al., J. Nat. Prod. 44 (1981) 745–747. doi: 10.1021/np50018a025

  2. [2]

     A.G. Sams, G.K. Mikkelsen, R.M. Brodbeck, X.S. Pu, A. Ritzén, Bioorg. Med. Chem. Lett. 21 (2011) 3407–3410. doi: 10.1016/j.bmcl.2011.03.103

  3. [3]

     I. Khan, A. Ibrar, N. Abbas, A. Saeed, Eur. J. Med. Chem. 76 (2014) 193–244. doi: 10.1016/j.ejmech.2014.02.005

  4. [4]

     U.A. Kshirsagar, Org. Biomol. Chem. 13 (2015) 9336–9352. doi: 10.1039/C5OB01379H

  5. [5]

     K. Hemalatha, G. Madhumitha, Eur. J. Med. Chem. 123 (2016) 596–630. doi: 10.1016/j.ejmech.2016.08.001

  6. [6]

     W.R. Bowman, M.R.J. Elsegood, T. Stein, G.W. Weaver, Org. Biomol. Chem. 5 (2007) 103–113. doi: 10.1039/B614075K

  7. [7]

     L. He, H. Li, J. Chen, X.F. Wu, RSC Adv. 4 (2014) 12065–12077. doi: 10.1039/C4RA00351A

  8. [8]

     T.M.M. Maiden, J.P.A. Harrity, Org. Biomol. Chem. 14 (2016) 8014–8025. doi: 10.1039/C6OB01402J

  9. [9]

     R.S. Rohokale, U.A. Kshirsagar, Synthesis 48 (2016) 1253–1268. doi: 10.1055/s-0035-1560413

  10. [10]

      X. Zhang, Y. Zhu, Y. Zhu, Z. Li, G. Zhang, Chin. J. Org. Chem. 39 (2019) 2392–2402. doi: 10.6023/cjoc201903025

  11. [11]

      C. Kaneko, K. Kasai, N. Katagiri, T. Chiba, Chem. Pharm. Bull. 34 (1986) 3672–3681. doi: 10.1248/cpb.34.3672

  12. [12]

      C. Tsukano, M. Okuno, H. Nishiguchi, Y. Takemoto, Adv. Synth. Catal. 356 (2014) 1533–1538. doi: 10.1002/adsc.201400078

  13. [13]

      G.R. Jazmín, D.M. Luis, Synthesis 53 (2021) 1471–1477. doi: 10.1055/s-0040-1705975

  14. [14]

      X. Zhou, Y. Xu, G. Dong, Nature Catal. 4 (2021) 703–710. doi: 10.1038/s41929-021-00661-7

  15. [15]

      Q. Dherbassy, S. Manna, C. Shi, et al., Angew. Chem. Int. Ed. 60 (2021) 14355–14359. doi: 10.1002/anie.202103259

  16. [16]

      X. Chen, B. Liu, C. Pei, et al., Org. Lett. 23 (2021) 7787–7791. doi: 10.1021/acs.orglett.1c02819

  17. [17]

      B. Sun, P. Huang, Z. Yan, et al., Org. Lett. 23 (2021) 1026–1031. doi: 10.1021/acs.orglett.0c04225

  18. [18]

      B. Sun, R. Shi, K. Zhang, et al., Chem. Commun. 57 (2021) 6050–6053. doi: 10.1039/D1CC02415A

  19. [19]

      Q.W. Gui, F. Teng, H. Yang, et al., Chem Asian J. 17 (2022) e202101139.

  20. [20]

      Z. Yang, Y. Shan, J.T. Yu, C. Pan, Eur. J. Org. Chem. 38 (2021) 5382–5385.

  21. [21]

      S. Eguchi, T. Suzuki, T. Okawa, et al., J. Org. Chem. 61 (1996) 7316–7319. doi: 10.1021/jo9609283

  22. [22]

      A. Kamal, K.V. Ramana, M.V. Rao, J. Org. Chem. 66 (2001) 997–1001. doi: 10.1021/jo0011484

  23. [23]

      O.I. Afanasyev, E. Podyacheva, A. Rudenko, et al., J. Org. Chem. 85 (2020) 9347–9360. doi: 10.1021/acs.joc.0c00794

  24. [24]

      P. Y. Bruice, Organic Chemistry, 4th ed., Pearson Prentice Hall, 2004.

  25. [25]

      G.Y. Li, Angew. Chem. Int. Ed. 40 (2001) 1513–1516. doi: 10.1002/1521-3773(20010417)40:8<1513::AID-ANIE1513>3.0.CO;2-C

  26. [26]

      N.V. Dubrovina, A. Borner, Angew. Chem. Int. Ed. 43 (2004) 5883–5886. doi: 10.1002/anie.200460848

  27. [27]

      T. Nemoto, T. Matsumoto, T. Masuda, et al., J. Am. Chem. Soc. 126 (2004) 3690–3691. doi: 10.1021/ja031792a

  28. [28]

      L. Ackermann, R. Born, Angew. Chem. Int. Ed. 44 (2005) 2444–2447. doi: 10.1002/anie.200462371

  29. [29]

      K. Dong, Z. Wang, K. Ding, J. Am. Chem. Soc. 134 (2012) 12474–12477. doi: 10.1021/ja305780z

  30. [30]

      K. Dong, Y. Li, Z. Wang, K. Ding, Angew. Chem. Int. Ed. 52 (2013) 14191–14195. doi: 10.1002/anie.201307903

  31. [31]

      C. Chen, Z. Zhang, S. Jin, et al., Angew. Chem. Int. Ed. 56 (2017) 6808–6812. doi: 10.1002/anie.201701394

  32. [32]

      R.J. Somerville, R. Martin, Angew. Chem. Int. Ed. 56 (2017) 6708–6710. doi: 10.1002/anie.201702188

  33. [33]

      S.Z. Tasker, E.A. Standley, T.F. Jamison, Nature 509 (2014) 299–309. doi: 10.1038/nature13274

  34. [34]

      A.L. Clevenger, R.M. Stolley, J. Aderibigbe, J. Louie, Chem. Rev. 120 (2020) 6124–6196. doi: 10.1021/acs.chemrev.9b00682

  35. [35]

      L. Süsse, B.M. Stoltz, Chem. Rev. 121 (2021) 4084–4099. doi: 10.1021/acs.chemrev.0c01115

  36. [36]

      H. Mori, K. Hasebe, M. Terano, Polymer 40 (1999) 1389–1394. doi: 10.1016/S0032-3861(98)00379-6

  37. [37]

      H.R. Yang, L.T. Zhang, D.D. Zang, Z.S. Fu, Z. Q. Fan, Catal. Commun. 62 (2015) 104–106. doi: 10.1016/j.catcom.2015.01.023

  38. [38]

      Y. Nakao, K.S. Kanyiva, T. Hiyama, J. Am. Chem. Soc. 130 (2008) 2448–2449. doi: 10.1021/ja710766j

  39. [39]

      Y. Nakao, H. Idei, K.S. Kanyiva, T. Hiyama, J. Am. Chem. Soc. 131 (2009) 5070–5071. doi: 10.1021/ja901153s

  40. [40]

      Y. Nakao, Y. Yamada, N. Kashihara, T. Hiyama, J. Am. Chem. Soc. 132 (2010) 13666–13668. doi: 10.1021/ja106514b

  41. [41]

      C.C. Tsai, W.C. Shih, C.H. Fang, et al., J. Am. Chem. Soc. 132 (2010) 11887–11889. doi: 10.1021/ja1061246

  42. [42]

      W.C. Lee, C.H. Chen, C.Y. Liu, et al., Chem. Commun. 51 (2015) 17104–17107. doi: 10.1039/C5CC07455J

  43. [43]

      S. Liu, J. Sawicki, T.G. Driver, Org. Lett. 14 (2012) 3744–3747. doi: 10.1021/ol301606y

  44. [44]

      W.B. Zhang, X.T. Yang, J.B. Ma, Z.M. Su, S.L. Shi, J. Am. Chem. Soc. 141 (2019) 5628–5634. doi: 10.1021/jacs.9b00931

  45. [45]

      C.S. Wang, S.D. Monaco, A.N. Thai, et al., J. Am. Chem. Soc. 142 (2020) 12878–12889. doi: 10.1021/jacs.0c06412

  46. [46]

      P.A. Donets, N. Cramer, J. Am. Chem. Soc. 135 (2013) 11772–11775. doi: 10.1021/ja406730t

  47. [47]

      Q.S. Liu, D.Y. Wang, Z.J. Yang, et al., J. Am. Chem. Soc. 139 (2017) 18150–18153. doi: 10.1021/jacs.7b09947

  48. [48]

      Y.X. Wang, S.L. Qi, Y.X. Luan, et al., J. Am. Chem. Soc. 140 (2018) 5360–5364. doi: 10.1021/jacs.8b02547

  49. [49]

      Y.X. Wang, F.P. Zhang, Y.X. Luan, M. Ye, Org. Lett. 22 (2020) 2230–2234. doi: 10.1021/acs.orglett.0c00432

  50. [50]

      R.H. Wang, J.F. Li, Y. Li, et al., ACS Catal. 11 (2021) 858–864. doi: 10.1021/acscatal.0c04585

  51. [51]

      K.B. Selim, Y. Matsumoto, Y. Tomioka, Angew. Chem. Int. Ed. 48 (2009) 8733–8735. doi: 10.1002/anie.200904676

  52. [52]

      O'H. David, T. Mustafa, Tetrahedron: Asymmetry 10 (1999) 1189–1192. doi: 10.1016/S0957-4166(99)00095-6

  53. [53]

      C. Narendra, M. Sonali, K.G. Sunil, Tetrahedron: Asymmetry 19 (2008) 2721–2730. doi: 10.1016/j.tetasy.2008.12.010

  54. [54]

      D.A. Klumpp, S.L. Aguirre, G.V. Sanchez, S.J. Leon, Org. Lett. 3 (2001) 2781–2784. doi: 10.1021/ol016408y

  55. [55]

      J.S. Bair, Y. Schramm, A.G. Sergeev, et al., J. Am. Chem. Soc. 136 (2014) 13098–13101. doi: 10.1021/ja505579f

• 

  Figure 1  Natural products and drug molecules of 4-oxoquinazoline skeleton.

  下载: 全尺寸图片 幻灯片
  

  Scheme 1  Selective cyclization of 4-oxoquinazolines with tethered alkenes or functional group-substituted alkyl chain.

  下载: 全尺寸图片 幻灯片
  

  Scheme 2  Traditional chiral SPO1-5 and synthesis of new chiral SPO6-11.

  下载: 全尺寸图片 幻灯片
  

  Scheme 3  Scope of substrates. Standard reaction conditions: 1 (0.2 mmol), dioxane (2.0 mL), 5 mol% Ni(cod)₂, 40 mol% AlMe₃, 10 mol% SPO10, room temperature, under N₂ for 24 h; ^a 10 mol% Ni(COD)₂, 15 mol% PPh₃, 48 h; ^b 10 mol% Ni(cod)₂, 60 h; ^c 10 mol% Ni(cod)₂, 10 mol% SPO6, 15 mol% PPh₃, 80 ℃, 48 h; ^d 10 mol% Ni(cod)₂, 10 mol% SPO11, 40 ℃, 72 h; ^e 10 mol% Ni(cod)₂, 10 mol% SPO11, 60 ℃, 60 h; ^f 10 mol% Ni(cod)₂; ^g 10 mol% Ni(cod)₂, 10 mol% SPO6, 15 mol% PPh₃, 60 ℃, 72 h; ^h 10 mol% Ni(cod)₂, 40 ℃, 80 h; ⁱ 10 mol% Ni(cod)₂, 15 mol% PPh₃, 80 ℃, 48 h; ^j 10 mol% Ni(cod)₂, 80 ℃, 48 h.

  下载: 全尺寸图片 幻灯片
  

  Scheme 4  Extended experiments.

  下载: 全尺寸图片 幻灯片
  

  Scheme 5  Plausible mechanism.

  下载: 全尺寸图片 幻灯片

  Table 1.  Conditions optimization. ^a

  下载: 导出CSV
•